tAnGo Trial
tAnGo: A randomised phase III trial of gemcitabine in paclitaxel-containing epirubicin based adjuvant chemotherapy for women with early stage breast cancer
| Chief Investigators: |
Prof Christopher Poole |
| Sponsor: |
University of Birmingham |
| Funder: |
Educational grants from:
Breast Cancer Research
Bristol-Myers Squibb
Lilly Industries Ltd
Pharmacia
Roche Pharmaceuticals
Endorsed by Cancer Research UK
|
| Disease Site: |
Breast Cancer |
| Trial Type: |
Clinical Trial of an Investigational Medicinal Product |
| Status: |
Analysis |
| ISRCTN Reference Number: |
51146252 |
| Open to New Sites? |
No |
| Recruitment Start Date: |
22-Aug-2001
|
| Recruitment End Date: |
28-Nov-2004 |
| CRCTU Trial Management Team: |
Team B |
| Trial Email Address: |
tango@trials.bham.ac.uk |
The tAnGo trial was a large research study which looked at a new combination of chemotherapy drugs for the treatment of early stage breast cancer. The trial was designed to find out whether this new combination of drugs is any better than the best currently available treatment in terms of improving the long-term outlook of patients diagnosed with early stage breast cancer. 3152 patients participated in the tAnGo trial from hospitals all over the UK and Ireland.
Please note that the trials team cannot give individual’s clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible.
Trial summary
Trial protocol
Please Note:
Clinical trial protocols are complex technical documents which should only be used for the treatment of patients taking part in the trial. Investigators please ensure you have R&D approval for this specific version of the protocol before using as a reference.
Other websites